Literature DB >> 24759143

The mechanism underlying activation of factor IX by factor XIa.

David Gailani1, Yipeng Geng2, Ingrid Verhamme2, Mao-fu Sun2, S Paul Bajaj3, Amanda Messer3, Jonas Emsley4.   

Abstract

Factor XI (fXI) is the zymogen of a plasma protease, factor XIa (fXIa), that contributes to thrombin generation during blood coagulation by proteolytic conversion of factor IX (fIX) to factor IXaβ (fIXaβ). There is considerable interest in fXIa as a therapeutic target because it contributes to thrombosis, while serving a relatively minor role in hemostasis. FXI/XIa has a distinctly different structure than other plasma coagulation proteases. Specifically, the protein lacks a phospholipid-binding Gla-domain, and is a homodimer. Each subunit of a fXIa dimer contains four apple domains (A1 to A4) and one trypsin-like catalytic domain. The A3 domain contains a binding site (exosite) that largely determines affinity and specificity for the substrate fIX. After binding to fXIa, fIX undergoes a single cleavage to form the intermediate fIXα. FIXα then rebinds to the A3 domain to undergo a second cleavage, generating fIXaβ. The catalytic efficiency for the second cleavage is ~7-fold greater than that of the first cleavage, limiting fIXα accumulation. Residues at the N-terminus and C-terminus of the fXIa A3 domain likely form the fIX binding site. The dimeric conformation of fXIa is not required for normal fIX activation in solution. However, monomeric forms of fXI do not reconstitute fXI-deficient mice in arterial thrombosis models, indicating the dimer is required for normal function in vivo. FXI must be a dimer to be activated normal by the protease fXIIa. It is also possible that the dimeric structure is an adaptation that allows fXI/XIa to bind to a surface through one subunit, while binding to its substrate fIX through the other.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Exosite; Factor IX; Factor XIa

Mesh:

Substances:

Year:  2014        PMID: 24759143      PMCID: PMC4017667          DOI: 10.1016/j.thromres.2014.03.020

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  29 in total

1.  Model for a factor IX activation complex on blood platelets: dimeric conformation of factor XIa is essential.

Authors:  D Gailani; D Ho; M F Sun; Q Cheng; P N Walsh
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

2.  Solution structure of the A4 domain of factor XI sheds light on the mechanism of zymogen activation.

Authors:  Dharmaraj Samuel; Hong Cheng; Paul W Riley; Adrian A Canutescu; Chandrasekaran Nagaswami; John W Weisel; Zimei Bu; Peter N Walsh; Heinrich Roder
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-20       Impact factor: 11.205

3.  Location of the disulfide bonds in human coagulation factor XI: the presence of tandem apple domains.

Authors:  B A McMullen; K Fujikawa; E W Davie
Journal:  Biochemistry       Date:  1991-02-26       Impact factor: 3.162

4.  Association of factor XI and high molecular weight kininogen in human plasma.

Authors:  R E Thompson; R Mandle; A P Kaplan
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

5.  A sequential mechanism for exosite-mediated factor IX activation by factor XIa.

Authors:  Yipeng Geng; Ingrid M Verhamme; Amanda Messer; Mao-fu Sun; Stephen B Smith; S Paul Bajaj; David Gailani
Journal:  J Biol Chem       Date:  2012-09-07       Impact factor: 5.157

6.  Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein.

Authors:  K Fujikawa; D W Chung; L E Hendrickson; E W Davie
Journal:  Biochemistry       Date:  1986-05-06       Impact factor: 3.162

Review 7.  Step-by-step evolution of vertebrate blood coagulation.

Authors:  R F Doolittle
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2009-08-10

8.  Activation of factor XI by products of prothrombin activation.

Authors:  Anton Matafonov; Suryakala Sarilla; Mao-fu Sun; John P Sheehan; Vladimir Serebrov; Ingrid M Verhamme; David Gailani
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

9.  Evolution of the contact phase of vertebrate blood coagulation.

Authors:  M B Ponczek; D Gailani; R F Doolittle
Journal:  J Thromb Haemost       Date:  2008-08-28       Impact factor: 5.824

10.  Characterization of Novel Forms of Coagulation Factor XIa: independence of factor XIa subunits in factor IX activation.

Authors:  Stephen B Smith; Ingrid M Verhamme; Mao-fu Sun; Paul E Bock; David Gailani
Journal:  J Biol Chem       Date:  2008-01-11       Impact factor: 5.157

View more
  15 in total

1.  Mini-review on "A novel one-step purification of mouse factor IX".

Authors:  Sumita Choudhury; William E Plautz; Cosette Zacarias; Rinku Majumder
Journal:  J Rare Dis Res Treat       Date:  2016

Review 2.  Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces.

Authors:  Benjamin Tillman; David Gailani
Journal:  Semin Thromb Hemost       Date:  2017-09-12       Impact factor: 4.180

3.  Structural Basis for Activity and Specificity of an Anticoagulant Anti-FXIa Monoclonal Antibody and a Reversal Agent.

Authors:  Lauren K Ely; Marco Lolicato; Tovo David; Kate Lowe; Yun Cheol Kim; Dharmaraj Samuel; Paul Bessette; Jorge L Garcia; Thomas Mikita; Daniel L Minor; Shaun R Coughlin
Journal:  Structure       Date:  2018-01-11       Impact factor: 5.006

Review 4.  An update on factor XI structure and function.

Authors:  Bassem M Mohammed; Anton Matafonov; Ivan Ivanov; Mao-Fu Sun; Qiufang Cheng; S Kent Dickeson; Chan Li; David Sun; Ingrid M Verhamme; Jonas Emsley; David Gailani
Journal:  Thromb Res       Date:  2017-10-10       Impact factor: 3.944

5.  A non-circulating pool of factor XI associated with glycosaminoglycans in mice.

Authors:  Bassem M Mohammed; Qiufang Cheng; Anton Matafonov; Ingrid M Verhamme; Jonas Emsley; Keith R McCrae; Owen J T McCarty; Andras Gruber; David Gailani
Journal:  J Thromb Haemost       Date:  2019-06-17       Impact factor: 16.036

6.  F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes.

Authors:  Alessio Branchini; Massimo Morfini; Barbara Lunghi; Donata Belvini; Paolo Radossi; Loredana Bury; Maria Luisa Serino; Paola Giordano; Dorina Cultrera; Angelo Claudio Molinari; Mariasanta Napolitano; Elisabetta Bigagli; Giancarlo Castaman; Mirko Pinotti; Francesco Bernardi
Journal:  J Thromb Haemost       Date:  2021-10-24       Impact factor: 16.036

7.  Removal of the C-Terminal Domains of ADAMTS13 by Activated Coagulation Factor XI induces Platelet Adhesion on Endothelial Cells under Flow Conditions.

Authors:  Kathleen S Garland; Stéphanie E Reitsma; Toshiaki Shirai; Jevgenia Zilberman-Rudenko; Erik I Tucker; David Gailani; András Gruber; Owen J T McCarty; Cristina Puy
Journal:  Front Med (Lausanne)       Date:  2017-12-20

8.  A factor XIa-activatable hirudin-albumin fusion protein reduces thrombosis in mice without promoting blood loss.

Authors:  William P Sheffield; Louise J Eltringham-Smith; Varsha Bhakta
Journal:  BMC Biotechnol       Date:  2018-04-05       Impact factor: 2.563

9.  Genetic analysis of a hemophilia B family with a novel F9 gene mutation: A STROBE-compliant article.

Authors:  Xue Lv; Tao Li; Hao Li; Hong-Yan Liu; Zhen Wang; Zhi-Ping Guo
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

10.  Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI.

Authors:  Chan Li; Kayleigh M Voos; Monika Pathak; Gareth Hall; Keith R McCrae; Ingrid Dreveny; Renhao Li; Jonas Emsley
Journal:  J Thromb Haemost       Date:  2019-03-19       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.